TNF and rheumatoid arthritis: Regarding the treatments, almost all the RA patients had synthetic-DMARDs (n = 154, 96%), glucocorticoids were used by 96 patients (60%), and biologic DMARDs were used by only 17 patients (11%), of them 4 had rituximab, 1 abatacept, and 12 anti-TNF agents (10 had etanercept, and 2 adalimumab).